> SIRT > Home > Online consultation


Dear patients,


welcome to our consultation session! This is where we happily answer any questions you have about Selective Internal Radiation Therapy (SIRT).


Please complete the form below and send us your enquiry. Your data is of course treated in the strictest confidence. We will do our best to reply as soon as possible. Please be patient if our answer takes a few days to arrive – this is because we are busy answering high volumes of enquiries. Thank you!



* Mandatory fields

Checklist for the first SIRT consultation


You should have the following documents ready for your consultation with your local specialist:


  • Confirmed tumour diagnosis (histology or imaging in the case of HCC)
  • Evidence of adequate liver and kidney function confirmed by up-to-date blood results performed no more than two weeks ago:
    • Liver enzymes GOT, GPT, GGT, LDH
    • Total bilirubin, direct and indirect
    • Alkaline phosphatase (AP)
    • Cholinesterase
    • Total protein, albumin
    • Coagulation parameters PTT, prothrombin time (Quick), INR
    • Creatinine
  • Imaging results based on CT, MRI, PET or PET/CT scans performed no more than four weeks ago:
    • To assess any ascites present (fluid on the abdomen)
    • To assess possible hepatic vein thrombosis
    • To rule out significant metastases outside the liver
    • To demonstrate adequate healthy liver tissue
  • Documentation of the disease with all treatment measures, in particularly systemic chemotherapy undergone, local therapies (trans-arterial chemo-embolisation, radio-frequency ablation) as well as surgical procedures
  • Evidence of tumour markers (if available):
    • AFP for primary cancer of the liver (HCC)
    • CEA, CA 19-9 for colorectal cancer
    • NSE, chromogranin A, serotonin for neuroendocrine tumours
  • Referral


You can also print out the checklist here.


PDF SIRT consultation checklist

More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: